RIGEL PHARMACEUTICALS INC

Insider CFO buying at $18‑$12 reveals confidence in Rigel’s rare‑disease pipeline, while selling options balances risk – a mixed signal for investors.

Rigel Pharmaceuticals insider moves: CEO sells, execs buy. Investor take‑away: tactical trades hint at upcoming earnings, pipeline, and regulatory milestones.

Insider buying signals confidence at Rigel Pharmaceuticals—CFO’s 20,636‑share purchase highlights executive optimism and potential upside.

Insider sell‑off at Rigel Pharma: EVP sells $206K worth of shares, amid other exec trades and rising social‑media buzz—what it signals for investors.